Tyra Biosciences, Inc. TYRA
Updated: 17 Jun 2026
No signal published yet
We already track Tyra Biosciences and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Tyra Biosciences, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Tyra Biosciences free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
In April 2024, Tyra Biosciences announced the FDA clearance of its Investigational New Drug application for TYRA-300 to proceed with a Phase 2 clinical trial for achondroplasia. The company also recently reported positive initial results from its SURF301 Phase 1/2 study in patients with advanced solid tumors.
What Firelda Watch includes for Tyra Biosciences, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Tyra Biosciences, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Tyra Biosciences free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more